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Abstract
Introduction—Persons who inject drugs (PWID) continue to be disproportionately affected by 
HIV. HIV testing is key to reducing HIV transmission by increasing awareness of HIV status and 
linking HIV-positive persons to care. Using data from PWID participating in CDC’s National HIV 
Behavioral Surveillance (NHBS) system, we examined prevalence of recent HIV testing among 
PWID by certain characteristics to guide interventions to increase HIV testing.
Methods—We analyzed NHBS data from PWID 18 years or older recruited via respondent-
driven sampling in 20 US cities in 2012. We examined demographic and behavioral factors 
associated with recent HIV testing (within 12 months before interview) using a Poisson model to 
calculate adjusted prevalence ratios (aPRs).
Results—Of 9555 PWID, 53% had recently tested for HIV. In multivariable analysis, HIV 
testing was more frequent among participants who visited a healthcare provider (aPR 1.50, P < 
0.001), participated in alcohol or drug treatment (aPR 1.21, P < 0.001), or received an HIV 
prevention intervention (aPR 1.26, P < 0.001). HIV testing was also more frequent among 
participants who received free sterile syringes (aPR 1.12, P < 0.001).
Discussion—Only half of PWID participating in NHBS in 2012 reported recent HIV testing. 
HIV testing was more frequent among participants who accessed health and HIV prevention 
services. To increase HIV testing among PWID, it is important for providers in healthcare and 
HIV prevention settings to proactively assess risk factors for HIV, including injection drug use, 
and offer a wide range of appropriate interventions, such as HIV testing.
✩These data were presented at the National HIV Prevention Conference in Atlanta, GA, December 8, 2015.
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1. Introduction
Persons who inject drugs (PWID) are disproportionately affected by HIV. Although PWID 
who reported injecting within the past 12 months comprised <1% of the U.S. population 
aged 13 years or older in 2011 (Lansky et al., 2014), injection drug use accounted for an 
estimated 20% of prevalent infections among persons living with diagnosed HIV infection in 
the United States at the end of 2012 (Centers for Disease Control and Prevention (CDC), 
2015d). Recent increases in heroin use in the United States (CDC, 2015g), outbreaks of viral 
hepatitis among PWID (CDC, 2015e), and a large outbreak of HIV among PWID in rural 
Indiana (CDC, 2015a) raise concerns about HIV transmission among PWID.
The CDC recommends that persons at increased risk of HIV infection, including PWID and 
their sex partners, undergo HIV screening at least annually (CDC, 2006). For HIV-positive 
persons, achieving awareness of HIV infection is the first step in linkage to medical care and 
services, which can lead to improved clinical outcomes (Castel et al., 2013; Panel on 
Antiretroviral Guidelines for Adults and Adolescents, 2014) and a reduced likelihood of 
HIV transmission (Celentano et al., 1994; Marks et al., 2005; Porco et al., 2004; Weinhardt 
et al., 1999). At the end of 2012, an estimated 13% of U.S. HIV infections among persons 
aged 13 years or older were undiagnosed (CDC, 2015f). Data from the CDC’s National HIV 
Behavioral Surveillance (NHBS), which helps health departments in 20 cities with high 
AIDS prevalence monitor HIV-related behaviors, indicated that among PWID in 2012, 9% 
of participants tested positive for HIV, of whom only 64% were aware of their infection 
(CDC, 2015c).
Reaching PWID with HIV prevention interventions, such as HIV testing, can be challenging. 
PWID comprise a unique population for whom risk behaviors, healthcare needs, and 
available resources may differ from the general population (CDC, 2012b). The CDC’s 
Expanded HIV Testing Initiative (ETI), launched in 2007 to facilitate HIV diagnosis and 
linkage to medical care among populations at risk, was expanded in 2010 to include PWID 
(CDC, 2011, 2012a).
We used NHBS data to understand factors associated with HIV testing among PWID 
(Gallagher et al., 2007). We hypothesized that there would be a positive association between 
the use of health/HIV prevention services and HIV testing, cementing the role that providers 
play in identifying risk behaviors and promoting HIV prevention services, including HIV 
testing.
2. Methods
NHBS data are collected in three-year rounds of annual rotating cycles which focus on one 
population per year; methods are described elsewhere (CDC, 2015b,c; Lansky et al., 2007). 
Data were collected from PWID participating in NHBS in 2012 in 20 cities—which together 
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comprised approximately 65% of AIDS cases in large urban areas in 2011 (CDC, 2013). 
Participants were recruited using respondent-driven sampling (Heckathorn, 1997; Salganik 
and Heckathorn, 2004). Participants who had injected drugs during the previous 12 months, 
were current residents of a participating city, were aged 18 years or older, and could 
complete the interview in spoken English or Spanish were eligible to participate. Those who 
were eligible and provided informed consent were administered an anonymous, in-person 
interview. Self-reported HIV-positive participants who received their HIV-positive result 
more than 12 months before interview (n = 562) were excluded from this analysis.
The standardized interview included questions regarding demographic characteristics, sexual 
and drug-use behaviors, and use of HIV prevention services. Participants were asked the 
month and year of their most recent HIV test. Those who reported an HIV test during the 12 
months before interview were considered to have tested recently; no other testing interval is 
discussed in this analysis. The time period measured for all other behavioral variables was 
also 12 months before interview. All participants were offered anonymous HIV testing, 
although information regarding HIV testing on the date of interview was not incorporated 
into this analysis. Incentives were offered for interview completion, HIV testing, and 
recruitment, with amounts determined locally. Activities for NHBS were approved by local 
institutional review boards for each participating city and by the CDC.
“Received HIV prevention intervention” is a composite measure based on having received 
individual- or group-level HIV prevention interventions. “Received free sterile syringes” 
refers to having received new sterile syringes for free—excluding those given by friends, 
relatives, or sex partners. “Receptive sharing of syringes” is defined as “using needles that 
someone else had already injected with.” A “healthcare provider” is any person providing 
care in a clinical setting.
We performed bivariate analysis using the chi-square test to examine the percentages of 
PWID who reported having an HIV test by key characteristics. To determine if recent HIV 
testing varied by selected characteristics, we used a Poisson model with robust standard 
errors clustered on recruitment chain to calculate adjusted prevalence ratios (aPRs) and 95% 
confidence intervals (CIs; Zou, 2004). We included variables with significant bivariate 
differences (P < 0.05) plus gender (Table 2). To adjust for respondent-driven sampling 
methods, we included peer network size, as determined by asking participants how many 
people they know locally who inject drugs. To compare HIV testing in cities that did and did 
not receive ETI funding for HIV testing among PWID, we incorporated city as a 
dichotomous variable based on receipt of ETI funding; 17 of 20 NHBS cities were in ETI 
jurisdictions (Table 1). All analyses were performed in SAS 9.3 (SAS Institute, Inc., Cary, 
NC).
Having health insurance increases the probability of visiting a healthcare provider which, as 
an intermediate step, obscures the relationship between health insurance status and HIV 
testing. We included both health insurance status and healthcare provider visit as covariates 
in our primary multivariable model, based on statistical significance in bivariate analysis. We 
then estimated a secondary model excluding healthcare provider visit to better understand 
the relationship between health insurance status and HIV testing.
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Demographic and other characteristics of the 9555 participants included in this analysis are 
described in Table 1. Among participants, 53% reported HIV testing (Table 2). HIV testing 
was more common among participants who visited a healthcare provider (aPR 1.50, P < 
0.001), who participated in alcohol or drug treatment (aPR 1.21, P < 0.001), and who 
received an HIV prevention intervention (aPR 1.26, P < 0.001). Participants who received 
free sterile syringes more frequently reported HIV testing than those who did not (aPR 1.12, 
P < 0.001). HIV testing was less common among participants who reported receptive 
syringe sharing than among those who did not (aPR 0.87, P < 0.001).
A higher proportion of participants with health insurance visited a healthcare provider 
compared with those without health insurance (89% versus 62%, P < 0.001). There was no 
significant difference in HIV testing for participants with health insurance versus those 
without when using the primary model that included healthcare provider visit (aPR 1.01, P = 
0.8), however having health insurance was positively associated with HIV testing when 
using the secondary model that excluded healthcare provider visit (aPR 1.09, P = 0.001) 
(Table 2). No interaction was noted between healthcare provider visit and health insurance 
status.
Among participants who did not undergo HIV testing in the 12 months before interview, 
38% reported no particular reason for not testing; 27% reported fear of an HIV diagnosis, 
19% thought they were low risk for infection, and 12% reported not having time.
4. Discussion
Despite the recommendation for at least annual HIV screening among PWID (CDC, 2006), 
only half of the PWID participating in NHBS in 2012 reported recent HIV testing. Recent 
HIV testing was more common among participants who utilized health and HIV prevention 
services such as healthcare providers, alcohol or drug treatment, and HIV prevention 
interventions. HIV testing was also more common among participants who received free 
sterile syringes and less common among participants who reported receptive syringe-sharing 
partners, highlighting the importance of services provided by syringe service programs. 
Even in healthcare and HIV prevention settings, though, there is much work to be done; a 
third to nearly a half of participants who visited a healthcare provider, participated in alcohol 
or drug treatment, received an HIV prevention intervention, or received free sterile syringes 
reported not undergoing recent HIV testing.
Primary care settings, emergency rooms (where nearly 40% reported they receive routine 
medical care), alcohol and drug treatment programs, community-based organizations, and 
syringe service programs all represent opportunities to engage PWID and offer HIV 
prevention services, such as HIV testing. According to our data, HIV testing was more 
frequent among participants with health insurance only once healthcare provider visit was 
excluded, possibly due to the large overlap in the participants reporting health insurance and 
the participants reporting a recent health-care provider visit. This suggests that one route by 
which health insurance increases HIV testing may be via increased opportunities to interact 
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with healthcare providers, where HIV testing can be offered. For PWID who encounter the 
healthcare system, a lack of HIV testing represents a missed opportunity.
The findings here are subject to several limitations. Because this study is cross-sectional, it 
is not possible to establish causality; the likelihood of undergoing HIV testing may be 
influenced by other factors, such as an intrinsic propensity for health seeking and risk 
avoidance behaviors. Also, because date of most recent HIV test was self-reported, social 
desirability and recall biases may affect estimates. Furthermore, because the true 
characteristics of the PWID population are unknown, the representativeness of the NHBS 
sample cannot be determined. The lack of standard methods for multivariable analysis of 
respondent-driven sampling data precluded a weighted analysis; our models were clustered 
on recruitment chain and included peer network size to control for respondent-driven 
sampling methods. No behavioral models or theories were applied to this study. Finally, 
because PWID were interviewed in 20 cities with high AIDS prevalence, findings from these 
cities might not be generalizable to other cities or circum-stances.
To reduce new HIV infections, it is essential to increase HIV testing. HIV testing among 
PWID participating in NHBS in 2012 was suboptimal. Nearly 40% of participants who did 
not report HIV testing cited no particular reason, indicating that perhaps increasing 
opportunities for HIV testing would increase uptake. Indeed, HIV testing was more frequent 
among PWID in NHBS cities that received funding for HIV testing as part of the CDC’s 
ETI. While linking persons at increased risk for HIV to health and HIV prevention services 
can increase HIV testing, the process of linkage is complicated and is not addressed here; 
what is apparent through this analysis is that HIV testing in healthcare and HIV prevention 
settings is underutilized. Obvious first steps to increasing rates of HIV testing among PWID 
are for providers in healthcare and HIV prevention settings to be more proactive in assessing 
risk factors for HIV (including injection drug use), to understand the complex social, 
medical, and structural factors that often accompany injection drug use, and to offer HIV 
prevention interventions, including HIV testing, where appropriate.
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Table 1





  Male 6850 (72)
  Female 2705 (28)
Race or ethnicity
  American Indian or Alaska Native 89 (1)
  Asian, Native Hawaiian, or other Pacific Islanders 43 (0.5)
  Black or African American 4159 (44)
  Hispanic or Latinoa 2306 (24)
  White 2611 (27)
  Other or multiple races 332 (3)
Age group (years)
  18–24 368 (4)
  25–29 654 (7)
  30–39 1826 (19)
  40–49 2591 (27)
  ≥50 4116 (43)
From city in ETIb jurisdiction
  No 1549 (16)
  Yes 8006 (84)
Education
  <High school 3263 (34)
  High school diploma or GED 3810 (40)
  >High school 2479 (26)
Annual household incomec
  At or below federal poverty level 7465 (79)
  Above federal poverty level 2019 (21)
Insurance status
  None 3831 (40)
  Somed 5711 (60)
Visited healthcare provider
  No 2124 (22)
  Yes 7427 (78)
Participated in alcohol or drug treatment
  No 6112 (64)
  Yes 3443 (36)
Received an HIV prevention intervention
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2012
Characteristic No. %
  No 7215 (76)
  Yes 2325 (24)
Received free sterile syringes
  No 4749 (50)
  Yes 4804 (50)
No. of receptive syringe-sharing partners
  None 6172 (65)
  At least one 3371 (35)
Frequency of injection
  Less than once a day 2766 (29)
  At least once a day 6786 (71)
Total 9555
Each variable may not add to total, due to missing values. All reported behaviors occurred during the 12 months before interview.
a
Hispanics or Latinos can be of any race.
b
CDC’s Expanded Testing Initiative: ETI jurisdictions: Atlanta, GA; Baltimore, MD; Boston, MA; Chicago, IL; Dallas, TX; Detroit, MI; Houston, 
TX; Los Angeles, CA; Miami, FL; Nassau, NY; New Orleans, LA; New York, NY; Newark, NJ; Philadelphia, PA; San Diego, CA; San Francisco, 
CA; Washington, DC; Not ETI jurisdictions: Denver, CO; San Juan, PR; Seattle, WA.
c
Poverty level is based on household income and household size.
d
Includes public, private, other, and multiple insurances.
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